Arrowstreet Capital’s CRISPR Therapeutics CRSP Stock Holding History

Arrowstreet Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-29,162	Closed	-$1.77M	–	1300
2022 Q2	$1.77M	Buy	+29,162	New	+$1.71M	﹤0.01%	812
2021 Q4	–	Sell	-47,100	Closed	-$5.27M	–	1484
2021 Q3	$5.27M	Sell	47,100 -33,900	-42%	-$4.26M	0.01%	930
2021 Q2	$13.1M	Buy	+81,000	New	+$9.85M	0.02%	755
2020 Q4	–	Sell	-6,281	Closed	-$525K	–	2323
2020 Q3	$525K	Buy	+6,281	New	+$557K	﹤0.01%	2002
2020 Q2	–	Sell	-260,996	Closed	-$11.1M	–	2328
2020 Q1	$11.1M	Buy	260,996 +157,196	+151%	+$8.12M	0.03%	451
2019 Q4	$6.32M	Buy	+103,800	New	+$5.67M	0.01%	788

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Arrowstreet Capital's CRSP Position: Q3 2022 in Review

Arrowstreet Capital sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 29,162 shares — an estimated $1.77M sold.

Arrowstreet Capital first reported a position in CRSP in Q4 2019 and held it in 6 quarters. The position peaked at $13.1M in Q2 2021. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

Arrowstreet Capital reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
Arrowstreet Capital sold 29,162 CRISPR Therapeutics shares in Q3 2022, an estimated $1.77M.
Arrowstreet Capital first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 6 quarters.
Arrowstreet Capital's CRISPR Therapeutics position peaked at $13.1M in Q2 2021.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Arrowstreet Capital's 13F filing for Q3 2022, filed 14 Nov 2022.